secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZIMMER BIOMET HOLDINGS, INC. (ZBH)
CIK:        0001136869
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0000950170-23-016423
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zimmer Biomet Q1 net sales $1.831B (+10.1% reported, +13.2% CC); raises FY2023 guidance
--------------------------------------------------------------------------------

- Q1 diluted EPS $1.11 GAAP, adjusted $1.89; net earnings $232.5M GAAP, $396.8M adjusted.
- U.S. knee sales $448.2M (+18.1% YoY); hip sales $252.3M (+12.3% YoY).
- Raises FY2023 adjusted EPS guidance to $7.40-$7.50 (prior $6.95-$7.15); reported revenue growth 5.0-6.0% (prior 1.5-3.5%).
- Completed acquisition of Embody, Inc., adding collagen-based biointegrative solutions to sports medicine.
- Launched Persona OsseoTi Keel Tibia for cementless knee replacement; ZBEdge platform enhancements at AAOS 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/0000950170-23-016423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1136869/000095017023016423/zbh-20230502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-016423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer